DALLAS, Oct. 24, 2022 (GLOBE NEWSWIRE) — Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene remedy firm targeted on creating and commercializing AAV-based gene therapies for the remedy of monogenic ailments of the central nervous system (CNS) in each uncommon and enormous affected person populations, immediately introduced that it’s going to host a convention name and webcast with slides to focus on Astellas Pharma’s strategic funding to assist the event of two of Taysha’s AAV-based gene remedy packages, TSHA-102 for Rett syndrome and TSHA-120 for large axonal neuropathy (GAN), on Tuesday, October 25, 2022, at 8:00 AM Eastern Time.
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS illness. With a singular concentrate on creating healing medicines, we goal to quickly translate our remedies from bench to bedside. We have mixed our staff’s confirmed expertise in gene remedy drug growth and commercialization with the world-class UT Southwestern Gene Therapy Program to construct an in depth, AAV gene remedy pipeline targeted on each uncommon and large-market indications. Together, we leverage our totally built-in platform—an engine for potential new cures—with a aim of dramatically enhancing sufferers’ lives. More info is accessible at www.tayshagtx.com.
Company Contact:
Kimberly Lee, D.O.
Chief Corporate Affairs Officer
Taysha Gene Therapies
[email protected]
Media Contact:
Carolyn Hawley
Evoke Canale
[email protected]
